As we have communicated previously, we are committed to finding a strategic partner to help us maximize the value of our Hepalife technology and will continue to keep you updated on our progress.
While we are encouraged about our progress over the past six months, a lot of work remains. With a strong team in place, a rejuvenated contract manufacturing business, an expanding sales and distribution network in our wound care business, the potential of expanding our wound care portfolio and a value proposition being developed around drug delivery, we are excited about the Company's future.
Critical Milestones planned for the second half of 2013 are as follows:
1) Generate early sales in our proprietary wound care products
2) Sign agreements with three additional partners to sell and market our products in the U.S.
3) Add one additional strategic partner to expand our portfolio of wound care technologies through licensing or distribution agreements
4) Demonstrate the proof of principle in our lidocaine study around topical drug delivery with hydrogel
As our company grows and meets its objectives, we remain committed to communicating word of our progress to all of our stakeholders. To meet the growing demand for accurate and timely information, we recently launched a new website. For those of you who have seen our old site, I know you will agree that the new site offers a more effective way to communicate to all of our stakeholders: our customers, our strategic partners and our shareholders. The site will continue to evolve into a world-class communication vehicle.
I once again thank you for being a supporter of Alliqua, Inc., and hope you find this update and transparency into the Company valuable.
Chief Executive Officer
About Alliqua, Inc.
Alliqua, Inc. (ALQA)
|SOURCE Alliqua, Inc.|
Copyright©2012 PR Newswire.
All rights reserved